BAM
CSTL icon

Blueshift Asset Management’s Castle Biosciences CSTL Stock Holding History

Blueshift Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,458
Closed -$251K – 523
2025
Q4 		$251K Buy
+6,458
New +$208K 0.07% 369

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blueshift Asset Management's CSTL Position: Q1 2026 in Review

Blueshift Asset Management sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 6,458 shares — an estimated $251K sold.

Blueshift Asset Management first reported a position in CSTL in Q4 2025 and held it in 1 quarter. The position peaked at $251K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Blueshift Asset Management reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Blueshift Asset Management sold 6,458 Castle Biosciences shares in Q1 2026, an estimated $251K.
  • Blueshift Asset Management first reported a position in Castle Biosciences in Q4 2025 and held it in 1 quarter.
  • Blueshift Asset Management's Castle Biosciences position peaked at $251K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Blueshift Asset Management's 13F filing for Q1 2026, filed 14 May 2026.